Phenotypes of resistance in community urinary tract isolates of Escherichia coli: Therapeutic implications;Fenotipos de resistencia en aislamientos urinarios de Escherichia coli en la comunidad: Implicaciones terapéuticas

Medicina Clinica

Volumn 120, Issue 10, 2003, Pages 361-364

  Alonso Sanz, Mercedes ^a   Abad Bécquer, M Isabel ^a  

^a Laboratorio Central de Análisis Clínicos   (Spain)

Author keywords

Antimicrobials; Community; Escherichia coli; Phenotypes; Resistance; Urinary infection

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFALOTIN; CEFEPIME; CEFOXITIN; CEFUROXIME; CEFUROXIME AXETIL; CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; NALIDIXIC ACID; NITROFURANTOIN; PIPERACILLIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; EMPIRICISM; ENTEROBACTER INFECTION; ENZYME SYNTHESIS; ESCHERICHIA COLI; HUMAN; NONHUMAN; OUTPATIENT; PATHOGENESIS; PHENOTYPE; RETROSPECTIVE STUDY; SPAIN; URINARY TRACT INFECTION; URINE CULTURE;

EID: 0038070428     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13044733     Document Type: Article

References (27)

1. Hooton TM, Stamm WE. Diagnosis and treatment of acute uncomplicated urinary tract infection. Infect Dis Clin North Am 1997;11:551-81.
2. Alós JI, Carnicero M. Consumo de antibióticos y resistencia bacteriana a los antibióticos: "algo que te concierne". Med Clin (Barc) 1997;109: 264-70.
3. Carrie AG, Zhanel GG. Antibacterial use in community practice. Assesing quantity, indications and appropiateness, and relationship to the development of antibacterial resistance. Drugs 1999;57:871-81.
4. Saura-Llamas J, Saturno Hernández PJ, Romero Román JR, Gaona Ramón JM, Gascón Cánovas JJ y Grupo de Evaluación y Mejora de los Protocolos Clínicos. Características de las guías clínicas de atención primaria que se asocian a una mayor calidad asistencial. Aten Primaria 2001; 28:525-34.
5. Gómez-Martínez J, Marco F, Mensa J, Espasa M, Martínez JA, Jiménez de Anta MT. Actividad in vitro de fluoroquinolonas y antibióticos beta-lactámicos administrados por vía oral frente a aislamientos clínicos de Escherichia coli. Rev Esp Quimio 1999;12:54-7.
6. Villar J, Baeza JE, De Diego D, Ruiz-Poveda A, González JC, Barba I. Bacteriología y resistencia en las infecciones urinarias ambulatorias. Aten Primaria 1996;18:315-7.
7. Llobera Cánaves J, Campoamor Landin F, Daviu Pastor A, Bestard Serra M, Rodríguez Moreno C, Muro Pascual V. Uso de antibióticos en atención primaria: tratamiento de la infección urinaria. Aten Primaria 1996;17:309-16.
8. National Committee for Clinical Labatory Standards (NCCLS). Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standard M7-A5. Wayne, Pensylvania: NCCLS, 2000.
9. Florijn A, Nijssen S, Schmitz FJ, Verhoef J, Fluit AC. Comparison of E test and double disk difusion test for detection of extended spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis 2002;21:241-3.
10. Sham DF, Thornsberry C, Mayfield DC, Jones ME, Karlowsky JA. Multidrug-resistant tract isolates of Escherichia coli: prevalence and patient demographics in the United States in 2000. Antimicrob Agents Chemother 2001;45:1402-6.
11. Zhanell GG, Karlowsky JA, Harding GKM, Carrie A, Mazzulli T, Low DE. The Canadian urinary isolate study group y Hoban DJ. A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicilin, mecillinam, nitrofurantoin, and ciprofloxacin. Antimicrob Agents Chemother 2000;44:1089-92.
12. Stapleton P, Wu PJ, King A, Shannon K, French G, Phillips I. Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrob Agents Chemother 1995;39:2478-83.
13. Oliver A, Pérez-Vázquez M, Marínez-Ferrer M, Baquero F, De Rafael L, Cantón R. Ampicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different β-lactam resistance phenotypes. Antimicrob Agents Chemother 1999;43:862-7.
14. Courvalin P. Interpretative reading of antimicrobial susceptibility test. ASM News 1992;58:368-75.
15. Livermore DM, Winstangley TG, Shannon KP. Interpretative reading: recognizing the unusual and infering resistance mechanisms from resistance phenotypes. J Antimicrob Chemother 2001;48(Suppl 1):87-102.
16. Navarro Risueño F, Miró Cardona E, Mirelis Otero B. Lectura interpretada del antibiograma de enterobacterias. Enferm Infecc Microbiol Clin 2002;20:225-34.
17. Einhorn AE, Neuhauser MM, Bearden DT, Quinn JP, Pendland SL. Extended-spectrum beta-lactamases: frequency, risk factors, outcomes. Pharmacotherapy 2002;22:14-20.
18. Daza R, Gutiérrez J. Piedrola G. Antibiotic susceptivility of bacterial strains isolated form part with community-acquired urinary tract infections. Int J Antimicrob Agents 2001;18:211-5.
19. Tenover FC, Mohammed MJ, Gorton TS, Dembech ZF. Detection and reporting of organisms producing extended spectrum beta-lactamases: survey of laboratories in Connecticut. J Clin Microbiol 1999;37:4065-70.
20. Sham DF, Tornsberry C, Mayfield DC, Jones ME, Warlowsky JA. Multidrug-resistant urinary tract isolates of Escherichia coli: prevalence and patient demographies in the United States in 2000. Antimicrob Agents Chemoter 2001;45:1402-6.
21. Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA 1999;281:736.
22. Warren JV, Abrutin E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pylonephritis in women. Clin Infect Dis 1999;29:745-8.
23. Alonso M, Ausejo M, Fernández I, Abad I, Siguín R. Área 11. Actualización del tratamiento farmacológico de las infecciones en adultos. Hoja de evaluación terapéutica 1999;2(15).
24. Garau M, Latorre A, Alonso-Sanz M. Fosfomicina: un antibiótico infravalorado en infecciones urinarias por Escherichia coli. Enferm Infecc Microbiol Clin 2001;19:462-6.
25. Cebrecos J, Torelló J, Del Valle O, Fernández J, Arnau JM. Consumo de quinolonas y aparición de resistencias. Rev Farmacol Clin Exp 1990; 7(Supl 1):102.
26. Soriano F. Selección de bacterias resistentes a los antibióticos: factores microbiológicos y farmacológicos. Med Clin (Barc) 2001;117:632-6.
27. Hooper DC. Mechanisms of action of antimicrobial: focus on fluorquinolones. Clin Infect Dis 2001;32(Suppl 1):9-15.